文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

化疗初治盆腔淋巴结阳性前列腺癌全盆腔及腹主动脉旁放疗的血液学毒性与骨髓剂量体积效应

Hematological Toxicity and Bone Marrow Dose-Volume Effects in Chemotherapy-Naïve Patients Treated With Whole Pelvic and Para-aortic Lymph Node Radiation Therapy For Pathologic Pelvic Lymph Node-Positive Prostate Cancer.
PubMed 文献 · Adv Radiat Oncol · 2026-05-28

该研究分析了75例接受全盆腔+腹主动脉旁放疗的化疗初治盆腔淋巴结阳性前列腺癌患者,中位随访57个月,无血液学毒性导致治疗中断,但所有血液参数显著下降,4级毒性仅见淋巴细胞减少(急性7%、晚期1%),低剂量骨髓照射体积(V3-V10)与晚期绝对淋巴细胞计数下降显著相关。

要点

  • 扩大野放疗耐受良好,无血液学毒性相关治疗中断。
  • 4级毒性仅淋巴细胞减少(急性7%、晚期1%),无3-4级贫血或2-4级血小板减少。
  • 低剂量骨髓照射体积(V3-V10)与晚期淋巴细胞计数下降独立相关。

核心结论

  • 扩大野放疗在化疗初治盆腔淋巴结阳性前列腺癌中临床耐受良好,无毒性相关治疗中断,但持续淋巴细胞减少值得关注。
  • 低剂量骨髓照射(V3-V10)与晚期绝对淋巴细胞计数下降存在剂量依赖关联,支持骨髓保护技术研究。

研究设计与样本

  • 研究纳入鲁汶大学医院PART研究前75例接受全盆腔+腹主动脉旁放疗的化疗初治盆腔淋巴结阳性前列腺癌患者,均接受24个月雄激素剥夺或抗雄激素治疗。
  • 纵向评估血液学变化,采用重复测量线性模型分析关联,并进行错误发现率校正。

主要发现

  • 中位随访57个月(中位年龄66岁),无血液学毒性导致治疗中断。
  • 放疗后所有血液参数显著下降(1、3、6、24个月均P < .01)。
  • 4级毒性仅淋巴细胞减少(急性7%、晚期1%),3级白细胞减少急性和晚期均为1%,未见3-4级贫血或2-4级血小板减少。
  • 下盆腔、全盆腔及全盆腔+腹膜后区域的低剂量体积(V3、V5、V10)越大,与晚期绝对淋巴细胞计数下降显著相关。
  • 绝对体积每增加100 cm3,晚期绝对淋巴细胞计数下降-0.04至-0.08×10^9/L(所有错误发现率P ≤ .01)。

关键数值与推荐

  • 低剂量骨髓体积参数V3、V5、V10与晚期绝对淋巴细胞计数下降显著相关(P ≤ .01)。
  • 绝对体积每增加100 cm3对应晚期绝对淋巴细胞计数下降-0.04至-0.08×10^9/L。

临床怎么用

  • 全盆腔+腹主动脉旁放疗在该人群中血液学耐受性良好,可考虑用于适合的盆腔淋巴结阳性前列腺癌患者。
  • 关注低剂量骨髓照射体积(V3-V10),探索骨髓保护技术以减少晚期淋巴细胞减少。

局限性

  • 研究为单中心前75例患者分析,样本量有限。
  • 未报告对照组,无法直接比较扩大野与标准盆腔放疗的毒性差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Whole pelvic radiation therapy combined with androgen-deprivation therapy improves prostate cancer-specific survival in pathologic pelvic lymph node-positive prostate cancer. Elective para-aortic radiation therapy may further improve clinical outcomes and is under investigation in the Para-Aortic Radiotherapy (PART) study (NCT03079323). This study investigated the effect of whole pelvic radiation therapy plus PART on hematological toxicity (HemT). METHODS AND MATERIALS: HemT and bone marrow (BM) dose-volume relationships were analyzed in the first 75 PART patients enrolled in the University Hospitals Leuven, all receiving 24 months of androgen-deprivation therapy or antiandrogen therapy. Hematological changes were assessed longitudinally. Associations were analyzed using linear models for repeated measures, with false discovery rate correction. RESULTS: At 57-months median follow-up (median age, 66 years), no HemT caused treatment interruption. All blood parameters declined significantly after radiation therapy (all P < .01 at 1, 3, 6, and 24 months). Grade 4 toxicity was limited to lymphopenia (acute 7%, late 1%), grade 3 leukopenia occurred in 1% acutely and late. No grade 3-4 anemia or grade 2-4 thrombocytopenia was seen. BM dosimetric analysis showed that larger low-dose volumes (V3, V5, and V10) in the lower pelvis, whole pelvis, and whole pelvis plus retroperitoneal region were significant associated with greater late absolute lymphocyte count (ALC) decline. Every 100 cm3 increase in absolute volume correlated with a late ALC decrease of -0.04 to -0.08 × 109 /L (all false discovery rates; P ≤ .01). CONCLUSIONS: Extended-field radiation therapy is clinically well tolerated in chemotherapy-naïve pathologic pelvic lymph node-positive prostate cancer patients, with no toxicity-related treatment interruptions. However, persistent lymphopenia was observed. Dose-dependent association between low-dose BM irradiation (V3-V10) and late ALC decline supports further research into BM-sparing techniques to reduce long-term toxicity.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. den Hartog J, De Meerleer G, Laenen A, et al. Hematological Toxicity and Bone Marrow Dose-Volume Effects in Chemotherapy-Naïve Patients Treated With Whole Pelvic and Para-aortic Lymph Node Radiation Therapy For Pathologic Pelvic Lymph Node-Positive Prostate Cancer. Adv Radiat Oncol. 2026. PMID: 42519375. doi:10.1016/j.adro.2026.102072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。